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Purpose: Localised prostate cancer diagnosis and management is increasingly complex due to its het-
erogeneous progression and prognostic subgroups. Pitfalls in current screening and diagnosis have
prompted the search for accurate and invasive molecular and genetic biomarkers for prostate cancer.
Such tools may be able to distinguish clinically signiﬁcant cancers from less aggressive variants to assist
with prostate cancer risk stratiﬁcation and guide decisions and healthcare algorithms. We aimed
to provide a comprehensive review of the current prostate cancer biomarkers available and in
development.
Methods: MEDLINE and EMBASE databases searches were conducted to identify articles pertaining to
the use of novel biomarkers for prostate cancer.
Results: A growing number of novel biomarkers are currently under investigation. Such markers include
urinary biomarkers, serology-based markers or pathological tissue assessments of molecular and genetic
markers. While limited clinical data is present for analysis, early results appear promising. Speciﬁcally, a
combination of serum and urinary biomarkers (Serum PSA + Urinary PCA3 + Urinary TMPRSS2-ERG
fusion) appears to provide superior sensitivity and speciﬁcity proﬁles compared to traditional diagnostic
approaches (AUC 0.88).
Conclusion: The accurate diagnosis and risk stratiﬁcation of prostate cancer is critical to ensure
appropriate intervention. The development of non-invasive biomarkers can add to the information
provided by current screening practices and allows for individualised risk stratiﬁcation of patients. The
use of these biomarkers appears to increase the sensitivity and speciﬁcity of diagnosis of prostate cancer.
Further studies are necessary to deﬁne the appropriate use and time points of each biomarker and their
effect on the management algorithm of prostate cancer.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is among the commonest newly diag-
nosed cancers in the Western world, with projections for
increased incidence over the following decades.1 Prostate speciﬁc
antigen (also known as PSA or human kallikrein-3) remains the
ﬁrst line and most commonly used serum biomarker for the
detection of PCa. The introduction of PSA has resulted in the
increased diagnosis of men with localized, early stage PCa.2 Iniversity of Melbourne, Austin Hea
rentschuk).
ciﬁc Prostate Society, Published bcurrent practice, controversy remains over its suitability and ef-
ﬁcacy as a screening tool for increasing early detection of PCa and
lowering mortality.3 An inherent limitation to PSA testing relates
to lack of speciﬁcity in the setting of PCa screening.4 There is great
clinical need for accurate screening for PCa to decrease unnec-
essary prostate biopsies.
Additionally, PSA provides poor differentiation of PCa
aggressiveness.4 PCa presents a difﬁcult entity to accurately risk
stratify due to its highly variable clinical course. Prostate biopsylth, Studley Road, Heidelberg, Victoria 3088, Australia.
y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
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limitations and its invasive nature increases the risk of adverse
events. Further, the PCa risk stratiﬁcation by PSA, prostate biopsy
Gleason score, or pTNM cancer stage may lead to understaging.5
Accurate staging and risk stratiﬁcation is critical, particularly
when considering active surveillance. As such, there is a critical
need for improved PCa biomarkers that are noninvasive and have
improved accuracy and risk stratiﬁcation properties.
This has led to the search for aids in the decision-making
algorithm of PCa that may give information on prognosis, add
diagnostic speciﬁcity, or act as screening tools. Over recent
decades, the development of molecular biomarker assays and
genetic assays has provided an avenue for PCa biomarker
development. Considerable research has resulted in a new panel
of tests that may improve determination of cancer presence,
aggressiveness, and prognosis. Emerging biomarkers include
those utilizing serum, urinary, or tissue samples as a test sub-
strate. In clinical practice, the utility of these biomarkers is var-
iable and may be used at different time points throughout the
care of a patient with suspected or diagnosed PCa. Speciﬁcally,
these biomarkers assist in diagnosis, guiding deﬁnitive treatment
options, determine the risk of ongoing monitoring versus inter-
vention, or provide risk stratiﬁcation in the setting of negative
initial biopsy.
There is still a need for a clear understanding of the role of
each of these tests in the diagnosis, management, and prognosis
of patients with PCa. This review explores the current literature
on biomarkers used in PCa screening. We have reviewed the
contemporary literature pertaining to different PCa biomarkers
including: ProPSA and PHI, the 4K score test, PCa antigen 3,Fig. 1. Appropriate timing of the use of these biomarkers in thetransmembrane serine protease protein 2 (TMPRSS2)-Erythro-
blastosis virus E26 Oncogene Homolog (ERG), ExoDx Prostate
Intelliscore, Second Chromosome Locus Associated with
Prostate-1 (SChLAP1), SelectMDx, ConﬁrmMDx, Oncotype DX PCa
assay, Prolaris, Decipher, and Embryonic Lethal, Abnormal Vision,
Drosophila-Like 1 (ELAVL1). We aim to objectively review current
biomarkers in PCa in order to further deﬁne the utility of these
tests and their role in PCa management. Fig. 1 is a guide to the
use and appropriate timing of the discussed biomarkers in the
role of a patient with suspected or proven PCa.
2. Serum-based PCa biomarkers
2.1. ProPSA and PHI
PSA is derived from an inactive precursor enzyme that contains
a pro leader sequence of seven amino acids, known as [-7]proPSA.
Activation occurs through posttranslational cleavage of its  7
amino acid (AA) pro leader sequence by human kallikreins 2 and 4
to form the mature 237 amino acid PSA molecule. Partial cleavage
of this leader sequence produces isoforms of proPSA depending on
how many amino acids remain attached to the PSA molecule, most
commonly [-4]proPSA, [-5]proPSA, and [-2]proPSA. The [-2]proPSA
variant has been found to be the most prevalent in PCa extracts.6
The Prostate Health Index (PHI, Beckman Coulter Inc., Brea, CA,
USA) is a mathematical formula which relies on the differing pro-
portions of the speciﬁc biomarkers (fPSA, tPSA, -2proPSA). This
formula provides additional information to assist in delineating
between benign prostatic conditions and PCa in men with sus-
pected PCa. Validation was provided by a multicenter, casecare of a patient with suspected or proven prostate cancer.
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benign digital rectal examination, and PSA between 2 ng/mL and
10 ng/mL underwent prostate biopsy. PHI was found to have
greater speciﬁcity (AUC 0.73) than PSA alone or other combinations
of pro PSAs.7 Furthermore, the study displayed that increasing PHI
values were associatedwith detection of clinically signiﬁcant PCa of
Gleason Grade 7 or higher. These ﬁndings were corroborated by
Fossati et al,6 who reported an association with PHI score and
poorer pathological outcomes on 489 patients treated with radical
prostatectomy. Whilst data regarding this test is immature, PHI
appears to be a promising, noninvasive biomarker that may
improve detection and provide prognostic information.
2.2. The 4Kscore test
Similar to PHI, the 4Kscore (OPKO Lab, Miami, FL, USA) test is
determined on serum levels of four human kallikreins: total PSA,
free PSA, intact PSA, and human kallikrein 2. These values are used
in combination with clinical information (age, Digital Rectal Ex-
amination (DRE) ﬁndings, and history of previous negative biopsy
result). These variables are placed into an algorithm and a patient-
speciﬁc percentage risk of having Gleason score 7 or more on
subsequent biopsy is provided.8 This recent prospective study by
Parekh et al8 examined the intervention of the 4K test on 1,012men
referred for prostate biopsy for clinical suspicion of PCa regardless
of PSA. The predictive accuracy of a biopsy result Gleason 3þ 4
was signiﬁcantly higher with the inclusion of the 4K test (compared
to PSA alone), with an AUC 0.821 [95% conﬁdence interval (CI)
0.790e0.852] versus 0.751 (95% CI 0.714e0.789), respectively.8 In
this diagnostic setting, the 4K score has been reported to have
reduced the number of prostate biopsies in a multicenter study of
611 patients.9 Additionally, there is evidence that the 4K score may
be able to identify higher risk PCas. Stattin et al10 conducted a case-
control study from a population based cohort over > 15 years using
Swedish Cancer registry data and cryopreserved blood from men
aged 40 years, 50 years, and 60 years. Improved prediction of risk of
metastasis over a 20 year period was found to correlate with
increasing 4K score.10 Similar to PHI, the 4K score is a noninvasive
biomarker that improves diagnostic accuracy for clinically signiﬁ-
cant PCa compared to PSA alone.
3. Urinary biomarkers
3.1. PCa antigen 3
PCa antigen 3 (PCA3 e Progensa Test Kit, Hologic, Marlborough,
MA, USA) involves noncoding RNA sequences from prostate speciﬁc
genes that are highly expressed in PCa cells. It is overexpressed in
PCa cells in comparison to normal or benign prostate cells.11 PCA3
scores reﬂect the ratio of PCA3 RNAmolecules to PSA RNAmolecules
detected in a patient’s urinary specimen following a digital rectal
examination. The current indication for the use of Progensa is in
men aged 50 years or older who have had one or more previous
negative prostate biopsies in whom a repeat biopsy would be rec-
ommended as standard of care. A PCA3 score< 25 is associated with
a decreased chance of PCa on subsequent repeat biopsy. PCA3 has
been shown to have a variable sensitivity, speciﬁcity, positive pre-
dictive value (PPV), and negative predictive value (NPV) depending
on the cutoff score chosen (PCA3 score of 25 or 35). A PCA3 score of
35 was associated with a sensitivity of 58e82%, speciﬁcity of
58e76%, PPV of 67e69%, and NPV of 87%, and an AUC of 0.68e0.87
(95% CI for 0.87: 0.81e0.92).12e14 Leyten et al14 further demon-
strated a difference in a PCA3 score of 25 and 35 with sensitivity and
speciﬁcity of 82.5% and 50.8%, respectively, for a PCA3 score of 25,
and 68.4% and 58.3% with a PCA3 score of 35. Furthermore, higherPCA3 scores have been correlated to tumor aggressiveness, sug-
gesting the PCA3 test has prognostic validity.15 PCA3 when used in
conjunction with PSA and DRE screening can lower the number of
unnecessary prostate biopsies in patients considered for initial
prostate biopsy or in men considered for repeat biopsy.16
3.2. TMPRSS2-ERG
TMPRSS2 is a prostate speciﬁc and androgen regulated gene that
codes for a fusion protein. This has been identiﬁed as an oncogene
for PCa with overexpression in > 50% of PCa cases. In PCa, the
TMPRSS2 gene fuses with the transcriptional factors and regulator
ERG (TMPRSS2-ERG) in ~48% of clinically localized PCa, but only
30% of hormone naïve metastases.17 Acting alone, TMPRSS2-ERG
has a low sensitivity of 24.3e37%, high speciﬁcity of 93%, and a
subsequent PPV of 94% after a DRE.11,14,18,19 However, in combina-
tion with serum PSA (cutoff of 10 ng/mL) and urinary PCA3,
TMPRSS2-ERG provides an improved accuracy in diagnosing PCa
with a sensitivity and speciﬁcity of 80% and 90%, respectively, and
AUC of 0.88 (95% CI 0.75e0.98).20
3.3. ExoDx prostate Intelliscore urine exosome assay
ExoDx (Exosome Diagnostics Inc., Cambridge, MA, USA) prostate
Intelliscore urine exosome assay used in conjunction with the
current standard of care is a novel marker produced to determine
the risk of Gleason 6, Gleason 7, and benign disease on initial bi-
opsy. ExoDx uses a urinary substrate, utilizing a three exosome
gene assay signature (ERG, PCA3, SPDEF) to construct a score.
McKiernan et al21 assessed 519 patients and determined that ExoDx
was predictive of high grade PCa (Gleason score> 7) on subsequent
initial biopsywith a sensitivity of 92% and speciﬁcity of 34%, an NPV
of 91%, and a PPV of 36% with an AUC¼ 0.77 (95% CI 0.71e0.83).21
This test again may reduce the number of potentially unnecessary
prostate biopsies.
3.4. SChLAP1
SChLAP1 (GenomeDx Biosciences, San Diego, CA, USA)
expression has been identiﬁed as a potential biomarker for the
risk of metastatic progression of PCa. Prensner et al22 using a
multivariate analysis of 1,008 patients showed that SchLAP1
expression (high or low) was a predictor of metastatic progres-
sion of PCa within 10 years (odds ratio 2.45, CI 95% 1.70e3.53,
P< 0.0001). Prensner et al22 similarly reported that SChLAP1 is
expressed in ~25% of PCas and may aid in the discrimination of
aggressive and indolent tumors. High SChLAP1 expression was
associated with a higher risk of biochemical recurrence, metas-
tases, death from PCa, and death from any cause at 10 years post
prostatectomy. They also found that it may be viable as an in-
dependent prognostic risk factor for metastasis. Adding the
SChLAP1 assay to the Decipher assay led to a signiﬁcant increase
in the prognostic potential of Decipher: from 0.77 (95% CI
0.72e0.81) to 0.79 (95% CI 0.74e0.83), P¼ 0.048.23 Prensner
et al23 also reported preliminary studies on post DRE urinary
SChLAP1 expression in a cohort of 230 patients. SChLAP1 was
integrated with PCA3 and TMPRSS2-ERG fusion expression with
SChLAP1 was able to detect some cancers not detected by the
other two methods (8%). SChLAP1 however had a lower sensi-
tivity than PCA3 and TMPRSS2-ERG fusion.23
3.5. SelectMDx
SelectMDx (MDxHealth, Irvine, CA, USA) is a urinary two gene
assay (HOXC6 and DLX1) used for the detection of high grade PCa
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patients who are considered for prostate biopsy or have previously
had negative biopsies, despite high risk factors for PCa (abnormal
digital rectal examination, family history of PCa, or high serum PSA
levels). Leyten et al24 validated a urinary three gene panel (HOXC6,
TDRD1, and DLX1) and demonstrated a higher accuracy (AUC 0.77;
95% CI 0.71e0.83) for detection of clinically signiﬁcant PCa when
compared to PSA and PCA3 (AUC 0.72; CI 0.68e0.78 and AUC 0.68;
95% CI 0.62e0.75, respectively). Recently, Van Neste et al25 further
validated these ﬁndings and compared them to other PCa gene
markers detected on urinalysis. This group performed two inde-
pendent prospective clinical trials (n¼ 905) and compared the
performance of individual and combination urinary biomarkers to
predict high grade PCa on biopsy. Their ﬁndings illustrated that the
strongest performers were HOXC6 and DLX1 with a sensitivity of
91%, a speciﬁcity of 36%, an NPV of 94%, a PPV of 27%, and an AUC of
0.76.25
4. Prostatic tissue biomarkers
4.1. ConﬁrmMDx
ConﬁrmMDx (MDxHealth, Irvine, Ca, USA) is an epigenetic test
that uses DNAmethylation in the detection of signiﬁcant PCa after a
negative prostate biopsy. It uses formalin-ﬁxed, parafﬁn-embedded
(FFPE) prostate tissue from biopsy. Three epigenetic biomarkers are
evaluated in ConﬁrmMDX - GSTP1, APC, and RASSF1.26 While not
FDA approved, current evidence suggests ConﬁrmMDx predicts the
risk of PCa on subsequent biopsy, with an NPV of 90%.26,27 A recent
study by Van Neste et al,28 assessed 803 patients from two previous
cohort studies that underwent two consecutive prostate biopsies
within a 30 month period. This group created an algorithm utilizing
patient age, histopathology of the ﬁrst cancer negative biopsy, and
the EpiScore (a DNA methylation intensity score). Low DNA
methylation in PCa-negative biopsies led to an NPV of 96% for high
grade cancer and AUC 0.762 (95% CI 0.68e0.84). Further to this, they
compared the clinical utility of this algorithm with PSA and PCa
prevention trail risk calculator for deciding to repeat biopsy. Using a
decision curve analysis, they demonstrated the largest reduction in
unnecessary repeat biopsies with the suggested algorithm.28
4.2. Oncotype DX PCa assay
Oncotype Dx for Prostate (Genomic Health Inc., Redwood City,
CA, USA) is a complex genetic-based assay used to further stratify
low to low-intermediate risk PCa (Gleason 6 or low volume Gleason
3þ 4). This assay assesses 12 cancer-related genes, representing
four different biological pathways and ﬁve reference genes. The
relevant results are combined to form the Genomic Prostate Score
(GPS). The GPS determines PCa aggressiveness by risk stratifying an
individual’s underlying tumor biology. This information assists
clinicians in assessing a patient’s suitability for active surveillance
or immediate treatment. A favorable score GPS< 20, improved the
conﬁdence of patients remaining on active surveillance, but unfa-
vorable patients should be evaluated for treatment.29,30 Each 20
point increase in GPS is associated with a 2.3-fold increased risk of
high grade disease (95% CI 1.5e3.7) and a 1.9-fold increased risk of
nonorgan conﬁned disease (95% CI 1.3e3.0) on ﬁnal pathology at
radical prostatectomy.31
4.3. Prolaris
The Prolaris score (Myriad Genomic Inc., Salt Lake City, UT,
USA) is a genomic assay that provides a Cell Cycle Progression
(CCP) score based on level of expression of mRNA of 31 cell cycleprogression genes relative to the level of 15 housekeeping
genes.32 CCP scores have shown a strong correlation on univariate
analysis with PCa death in a conservatively managed cohort after
biopsy (hazard ratio (HR) 2.02, 95% CI 1.62, 2.53).33 These ﬁndings
have been validated by the same group in a cohort of 585 men
who underwent needle biopsy with PCa death as the end point.
Similar HRs were found for each point increase in the CCP score
and showed signiﬁcance on multivariate analysis (1.76, 95% CI
1.44, 2.14, P 4.2  107).34 Accordingly, the Prolaris score appears
to provide information of suitability for enrolment to active sur-
veillance programs. CCP scores have also displayed their useful-
ness in adding prognostic information to patients diagnosed with
localized PCa. In a study of 582 patients who underwent prostate
biopsy and had CCP scoring on biopsy samples prior to pro-
gressing to prostatectomy, higher CCP scores were associated with
biochemical recurrence.35 This remained signiﬁcant after adjust-
ing for other prognostic clinical variables such as Gleason score
etc. (HR per score unit 1.47, 95% CI 1.23e1.76).35 In this study a
stronger independently associated risk was seen with rising CCP
score and metastatic disease on multivariate analysis (HR per
score unit 4.19, 95% CI 2.08e8.45).
4.4. Decipher
Decipher (GenomeDx Biosciences) is a 22 gene genomic classi-
ﬁer chosen by statistical selection to predict metastasis among high
risk radical prostatectomy patients. Decipher determines a patient's
probability of biochemical recurrence within 3 years or clinical
metastatic disease from 5 years to 10 years post radical prostatec-
tomy. At present, the reported indications for using decipher
include pT3 disease, positive margins, or a PSA rise after radical
prostatectomy, with patients given a genomic classiﬁer (GC) score
ranging from 0 to 1. Clinically, Decipher has undergone multiple
validation studies with a total of > 2,000 patients and an AUC of
0.79. Patients whowere deemed high risk with Decipher (GC 0.4)
and received adjuvant therapy had improved survival.3,36e38 Klein
et al36 evaluated the use of the Decipher GC with the National
Comprehensive Cancer Network on 57 patients from a previous
Decipher validation study from Cleveland Clinic. Using multivariate
analysis, they determined that Decipher predicted the risk of
metastasis at 10 years post radical prostatectomy (HR per 10% in-
crease 1.72, 95% CI 1.07e2.81, P¼ 0.02).36
4.5. ELAVL1
ELAVL1 (EnVision Kit; Dako, Glostrup, Denmark) is an RNA
binding protein expressed in a wide variety of tissues, including the
prostate, and may have a role in PCa progression. Melling et al39
reported that ELAVL1 may be an independent prognostic
biomarker in PCa and a predictor of unfavorable tumor phenotype
and early PSA recurrence after deﬁnitive therapy. This group
assessed 12,427 PCas specimens and determined that strong ELVAL1
staining was associated with high Gleason grade, advanced patho-
logical tumor stage, positive nodal status, and PSA recurrence
(P< 0.0001). ELAVL1 positivity was more frequent in cancers with
TMPRSS2-ERG fusions and the presence of known genomic de-
letions associated with PCa (PTEN, 5q21, 6q21, and 3p13 P< 0.0001).
5. Future developments
Developments in the ﬁeld of PCa biomarkers are ongoing with
many new markers currently in preclinical phases. No doubt in the
next decade, a considerable armamentarium of biomarkers will be
available for use by practicing clinicians. The lack of robust, accurate,
noninvasive PCa biomarkers highlights the need for future research.
Table 1
Summary of currently available biomarkers for use in prostate cancer detection or stratiﬁcation.
Name Company Molecular marker FDA Accuracy
Serum-based biomarkers
ProPSA & Prostate Health Index Beckman Coultier Inc., Brea, CA, USA PSA
Free PSA
[2]proPSA
Yes AUC 0.703
Spec 16%, Sens 95%
4K score test OPKO Lab, Miami, FL, USA Human Kallikrien
Assay (fPSA, PSA, tPSA, hK2)
No AUC 0.82
Urinary biomarkers
Prostate cancer antigen
3 (Progensa)
Hologic, Marlborough, MA, USA PCA3 Yes AUC 0.68e0.87
TMPRSS2-ERG N/A TMPRSS2-ERG fusion No Sens 24.3e37%, Spec 93%, PPV 94%
PCA3þ PSAþ TMPRSS2-ERG-AUC 0.88
ExoDx Prostate Intelliscore
urine exosome assay
Exosome Diagnostics Inc,
Cambridge, MA, USA
ERG, PCA3, & SPDEF No Sens 92%, Spec of 34%, NPV 91%,
PPV 36%, AUC 0.77
SChLAP1 GenomeDx Biosciences,
San Diego, CA, USA
SChLAP1 expression No In conjunction with Decipher, AUC 0.79
SelectMDx MDxHealth, Irvine, CA, USA HOXC6 & DLX1 No Sens 91%, Spec 36%, NPV 94%,
PPV 27%, AUC 0.76
Prostatic tissue-based
biomarkers
ConﬁrmMDx MDxHealth, Irvine, CA, USA DNA methylation of GSTP1,
APC, & RASSF1 genes
No NPV 96%
Oncotype DX Prostate
Cancer Assay
Genomic Health Inc.,
Redwood City, CA, USA
12 cancer related genes, & 5
reference genes
No Not reported
Prolaris score Myriad Genomic Inc., Salt Lake City, UT, USA 31 cell cycle progression genes No Not reported
Decipher GenomeDx Biosciences, San Diego, CA, USA 22 RNA biomarkers No AUC 0.79
ELAVL1 EnVision Kit; Dako,
Glostrup, Denmark
Embryonic Lethal,
Abnormal Vision, Drosophila-Like
1 (ELAVL1) expression
No Not reported
AUC, area under the curve; DNA, deoxyribonucleic acid; ELAVL1, Embryonic Lethal, Abnormal Vision, Drosophila-Like 1; NPV, negative predictive value; PCA3, prostate cancer
antigen 3; PPV, positive predictive value; PSA, prostate speciﬁc antigen; RNA, ribonucleic acid; SChLAP1, Second Chromosome Locus Associated with Prostate-1; Sens,
sensitivity; Spec, speciﬁcity; TMPRSS2-ERG, Transmembrane serine protease protein 2-Erythroblastosis virus E26 Oncogene Homolog.
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assays have recently been shown to be elevated in prostate tissues,
peripheral blood, and body ﬂuids of PCa patients, but did not reveal
the same increase in benign prostatic hypertrophy.40,41 Their utility
also lies in differentiating between patients with raised PSA from
benign prostatic hypertrophy and clinically signiﬁcant PCa, adding
to the speciﬁcity of diagnosis. In a recent study, this helped clini-
cians determine a need for prostate biopsy in patients with PSA
results in the “gray zone” and reduced biopsy rates by 10e50%.42
There currently appears to be a paucity of biomarkers assessing
speciﬁc timepoints in the care of a PCa patient (See Table 1). There
are minimal biomarkers currently for determining the risk of
missed cancer after negative transrectal or transperineal biopsy43
and the risk of progression following focal therapies.44 Further,
with the increasing use of active surveillance,45 biomarkers accu-
rately determining the risk of progression while on active surveil-
lance are required. The increased use of multiparametric magnetic
resonance imaging of the prostate in these clinical scenarios will
also potentially impact on the future role of such biomarkers.
6. Conclusion
Each of the tests discussed has a potentially unique role in the
screening, diagnosis, surveillance, and treatment of PCa. To date, no
formal algorithm has been created to determine the role of each of
these tests in PCa. There is a critical need for robust, prospective
comparative data to further deﬁne the role of each biomarker in
clinical practice.
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